PCSK9 and coronary artery disorder: Similarly, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have shown efficacy in the treatment of coronary artery disease, and upregulation of PCSK9 has been identified in human CAVD and promotes VIC calcification in vitro (210).